FDA Grants Priority Review for ENHERTU Supplement Application
The FDA has granted priority review for the supplemental application of ENHERTU (fam-trastuzumab deruxtecan-nxki) submitted by Daiichi Sankyo.
Asset
ENHERTU
Indication
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The FDA's grant of priority review for ENHERTU's supplemental application is significant as it may expedite the drug's entry into new indications, potentially reshaping competitive dynamics in the ADC oncology space. Portfolio teams must stay alert to shifts in market positioning as new data becomes available.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the FDA's final decision timeline and any announcements regarding new indications for ENHERTU.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.